CORONAVIRUS: DIAGNOSIS AND THERAPY IN HUMANS

VolverGo back

Resultados 440 results. LastUpdate Updated on 14/08/2022 [14:02:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Page1/18 nextPage   results/page


MACHINE LEARNING FOR EARLY DETECTION OF CELLULAR MORPHOLOGICAL CHANGES

Publication No.: WO2022170145A1 11/08/2022

Applicant:

VIQI INC [US]

Absstract of: WO2022170145A1

Methods and systems for machine learning are disclosed for early detection of morphological changes in cell condition of biological cells. In one disclosed embodiment, the development of vaccines and anti-virals are sped up using machine learning to identify viral plaques earlier than can be detected using human observation alone. In the disclosed embodiment, detecting morphological changes in virus-infected cells can be made before plaques caused by cell death are observable (typical cell death in 2-14 days). Machine learning brings high-content/high-throughput techniques to the study of virology for the development of novel anti-viral compounds. Machine learning can also be used to characterize the effectiveness of novel anti-viral compounds on rapidly mutating viral strains, such as influenza and SARS-CoV-2.

traducir

TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS

Publication No.: WO2022170155A2 11/08/2022

Applicant:

BIOHAVEN THERAPEUTICS LTD [US]

Absstract of: WO2022170155A2

Among other things, the present disclosure provides agents that can bind to viruses such as SARS-CoV-2 and/or cells infected thereby. In some embodiments, the present disclosure provides methods for preventing and/or treating conditions, disorders or diseases associated with SARS-CoV-2 infection. In some embodiments, the present disclosure provides methods for preventing and/or treating COVID-19.

traducir

MULTIPLEXED, CRISPR-BASED DIAGNOSTICS OF SARS-COV-2 IN AUTONOMOUS MICROFLUIDIC DEVICE

Publication No.: WO2022170013A1 11/08/2022

Applicant:

UNIV CONNECTICUT [US]

Absstract of: WO2022170013A1

Described herein is an autonomous, rapid, sensitive, point-of-care target nucleic acid detection system and method based on CRISPR/Cas system. The system and method allow naked eye visualization of multiple target nucleic acid molecules simultaneously in a biological sample in less than an hour. Use of the system and method for multiplex gene diagnosis of SARS-CoV-2 is exemplified.

traducir

SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF

Publication No.: WO2022169834A2 11/08/2022

Applicant:

UNIV MICHIGAN REGENTS [US]

Absstract of: WO2022169834A2

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.

traducir

RECOMBINANT SUPER-COMPOUND INTERFERON (RSIFN-CO) FOR TREATING COVID-19 PATIENTS WITH OR WITHOUT SYMPTOMS

Publication No.: WO2022166885A1 11/08/2022

Applicant:

SICHUAN HUIYANG LIFE SCIENCE & TECH CORP [CN]

Absstract of: WO2022166885A1

The present invention discloses a method for preventing and/or treating COVID-19 (SARS-Cov-2) coronavirus infection by administering to a subject in need thereof a therapeutically effective dose of recombinant super-compound interferon (rSIFN-co) for a period. In one embodiment, the dose is from 1.0 to 100 μg per day and the period is at least 3 days and up to 30 days. In one embodiment, the rSIFN-co is administered by nasal spray, pharynx spray or intravenous injection.

traducir

MASS SPECTROMETRY MODEL COMPRISING MARKER POLYPEPTIDES FOR DIAGNOSING COVID-19 PNEUMONIA

Publication No.: WO2022166493A1 11/08/2022

Applicant:

BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO LTD [CN]

CN_114858904_PA

Absstract of: WO2022166493A1

A marker polypeptide composition for detecting COVID-19 pneumonia, which comprises 29 marker polypeptides having specific mass-to-charge ratios, and which can determine whether a sample is from a person afflicted by COVID-19 pneumonia by means of analyzing the expression of a marker polypeptide. Further provided are uses such as a mass spectrometry model prepared according to said marker polypeptide composition and a product that diagnoses COVID-19 pneumonia. A combination of a plurality of marker proteins having differences being searched for among people afflicted by COVID-19 pneumonia and controls comprising normal people, people afflicted by pulmonary tuberculosis, and people having a COVID-19 pneumonia-type symptom is proposed for the first time, innovating a traditional research approach where searching for marker polypeptides was limited to only normal people and people afflicted with COVID-19 pneumonia, an infection which has a symptom similar to COVID-19 pneumonia and causes a false positive result is effectively prevented, said invention is simple to operate, has low detection costs and high accuracy, and is anticipated to be used in large-scale screening for COVID-19 pneumonia.

traducir

CONSTRUCTION METHOD FOR MASS SPECTRUM MODEL FOR DIAGNOSING COVID-19

Publication No.: WO2022166494A1 11/08/2022

Applicant:

BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO LTD [CN]

CN_114858907_PA

Absstract of: WO2022166494A1

A characteristic polypeptide composition for detecting COVID-19, comprising 29 characteristic polypeptides having specific mass-to-charge ratios. By analyzing the expression of the characteristic polypeptides, whether a sample is a COVID-19 patient can be determined. Also provided is use of the characteristic polypeptide composition in preparation of a mass spectrum model and a product for diagnosing COVID-19, etc. For the first time, an approach of finding a plurality of characteristic protein combinations having differences from COVID-19 patients/normal people, pulmonary tuberculosis patients, and a control having COVID-19 type symptoms is proposed, and a conventional search approach for finding characteristic polypeptides merely from normal people and COVID-19 patients is broken through, infection of false positive results having symptoms similar to those of COVID-19 is effectively avoided, operations are simple, detection cost is low, accuracy is high, and the present invention is expected to be used for large-scale screening of COVID-19.

traducir

USE OF CHARACTERISTIC POLYPEPTIDE COMPOSITION AND MASS SPECTROMETRY MODEL FOR PREPARING COVID-19 DETECTION PRODUCT

Publication No.: WO2022166487A1 11/08/2022

Applicant:

BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO LTD [CN]

CN_114858905_PA

Absstract of: WO2022166487A1

Provided is a characteristic polypeptide composition for detecting COVID-19. The characteristic polypeptide composition comprises 29 characteristic polypeptides having a specific mass-to-charge ratio. Whether the sample belongs to a patient with COVID-19 can be determined by means of analysing the expression of the characteristic polypeptides. Also provided are uses of a mass spectrometry model prepared according to the characteristic polypeptide composition, a product for diagnosing COVID-19, etc. Searching for multiple combinations of characteristic proteins having differences according to patients with COVID-19/normal people, patients with tuberculosis and COVID-19 type symptoms controls breaks traditional research thought that is only limited to the search for characteristic polypeptides in normal people and patients with COVID-19, effectively avoids infection with false positive results similar to the symptoms of COVID-19, and has a simple operation, low detection costs, high accuracy, and is expected to be used for large-scale screening for COVID-19.

traducir

CHARACTERISTIC POLYPEPTIDE COMPOSITION FOR DIAGNOSING COVID-19

Publication No.: WO2022166486A1 11/08/2022

Applicant:

BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO LTD [CN]

CN_114858903_PA

Absstract of: WO2022166486A1

Provided is a characteristic polypeptide composition for detecting COVID-19, comprising 29 characteristic polypeptides having specific mass-to-charge ratios. By analyzing the expression of the characteristic polypeptides, whether the sample is a COVID-19 patient can be determined. Also provided is use of a mass spectrum model prepared according to the characteristic polypeptide composition in a product for diagnosing COVID-19, etc. For the first time, an approach of finding a plurality of characteristic protein combinations having differences according to COVID-19 patients/normal people, pulmonary tuberculosis patients, and controls having COVID-19 type symptoms is proposed, a conventional search approach for finding the characteristic polypeptides only from the normal people and the COVID-19 patients is broken through, infection of false positive results having symptoms similar to those of COVID-19 is effectively avoided, the advantages of simple operation, low detection cost, and high accuracy are achieved, and the present invention is expected to be used for large-scale screening of COVID-19.

traducir

KIT FOR DIAGNOSING COVID-19

Publication No.: WO2022166485A1 11/08/2022

Applicant:

BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO LTD [CN]

CN_114858906_PA

Absstract of: WO2022166485A1

A characteristic polypeptide composition for detecting COVID-19, comprising 29 characteristic polypeptides having a specific mass-to-charge ratio. Whether the sample belongs to a patient with COVID-19 can be determined by means of analysing the expression of the characteristic polypeptides. Also provided are uses of a mass spectrometry model prepared according to the characteristic polypeptide composition, a product for diagnosing COVID-19, etc. It was the first time to propose to search for multiple combinations of characteristic proteins having differences according to patients with COVID-19/normal people, patients with tuberculosis and COVID-19 type symptoms controls with which breaks traditional research thought that is only limited to the search for characteristic polypeptides in normal people and patients with COVID-19, effectively avoids infection with false positive results similar to the symptoms of COVID-19, and has a simple operation, low detection costs, high accuracy, and is expected to be used for large-scale screening for COVID-19.

traducir

NEUTRALIZING ANTIBODY TESTING AND TREATMENT

Publication No.: US2022252588A1 11/08/2022

Applicant:

SAPPHIRE BIOTECH INC [US]

Absstract of: US2022252588A1

A method for detection and measurement of neutralizing antibody levels to SARS-CoV-2 in a test-specimen, said method comprising obtaining a test-specimen from a subject, transferring the test-specimen to a sample well of a test-cassette, wherein the cassette further comprises a sample pad, a conjugate pad, a nitrocellulose membrane and an absorbent pad, wherein the sample pad comprises ACE2 or a functional fragment thereof, wherein the conjugate pad comprises a plurality of viral-ACE2-binding protein coupled to a plurality of labels, adding a buffer and reading the results from the test-cassette.

traducir

METHODS AND DEVICES FOR DETECTING A PATHOGEN AND ITS MOLECULAR COMPONENTS

Publication No.: US2022252584A1 11/08/2022

Applicant:

UNIV CALIFORNIA [US]

WO_2022165532_A1

Absstract of: US2022252584A1

Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.

traducir

ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF

Publication No.: US2022251174A1 11/08/2022

Applicant:

TALEM THERAPEUTICS LLC [US]

WO_2022165039_A1

Absstract of: US2022251174A1

The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.

traducir

AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS)

Publication No.: US2022249655A1 11/08/2022

Applicant:

FEDERAL STATE BUDGETARY INSTITUTION NATIONAL RES CENTRE FOR EPIDEMIOLOGY AND MICROBILOGY NAMED [RU]

WO_2022086364_A1

Absstract of: US2022249655A1

The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in lyophilized (freeze-dried) form, which contains a single active component, comprising the expression vector including either the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, and an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the genome of the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, and an integrated expression cassette is selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The genome of the recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution for reconstitution of the lyophilized form of the agent may contain the following, mass %: tris from 0.0180-0.0338; sodium chloride from 0.1044-0.1957; sucrose from 5.4688-10.2539; magnesium chloride hexahydrate from 0.0015-0.0028; EDTA from 0.0003-0.0005; polysorbate-80 from 0.0037-0.0070; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.

traducir

2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUOROARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRO-DRUGS AND USES THEREOF

Publication No.: US2022251134A1 11/08/2022

Applicant:

SOUTHERN RES INST [US]

CN_114502174_PA

Absstract of: US2022251134A1

The present disclosure is concerned with 2,4,7-substituted-7-deaza-2′-deoxy-2′-fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), 229E, NL63, OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

SYSTEMS AND METHODS FOR DETECTING THE PRESENCE OF AN ANALYTE, SUCH AS SARS-COV-2, IN A SAMPLE

Publication No.: US2022251671A1 11/08/2022

Applicant:

ADL DIAGNOSTICS [US]

Absstract of: US2022251671A1

Methods for detecting an analyte in a sample are disclosed. The method can include depositing the sample in an instrument, such as a Loop-Mediated Isothermal Amplification (LAMP) instrument that is configured to selectively amplify an analyte, such as a characteristic portion of a genome of a pathogen. A moving average of the quantity of the analyte at an instance of time can be compared to a sum of (1) the moving average for a previous instance of time and (2) a multiple of the moving standard deviation at the previous instance of time. If the quantity of the analyte at the instance of time is greater than the sum of (1) the moving average for a previous instance of time and (2) a multiple of the moving standard deviation at the previous instance of time, it can be an indication that the sample is positive for the analyte.

traducir

CATALYTIC AMPLIFICATION BY TRANSITION-STATE MOLECULAR SWITCHES FOR DIRECT AND SENSITIVE DETECTION OF SARS-COV-2

Publication No.: WO2022169412A1 11/08/2022

Applicant:

NAT UNIV SINGAPORE [SG]

Absstract of: WO2022169412A1

The present invention relates to the detection of target nucleic acids using enzyme-assisted nanotechnology. More specifically, the present invention provides a molecular nanotechnology in the form of a transition-state DNA-enzyme molecular switch and methods of use that enables direct and sensitive detection of viral RNA targets in native clinical samples. In one embodiment, the detection comprising steps of providing a composition comprising at least one DNA polymerase enzyme, at least one enhancer, and at least one DNA polymerase inhibitor, wherein the DNA polymerase inhibitor is recognized and bound by the DNA polymerase enzyme via its conserved region, and is complementary to a portion of the enhance via its variable region. In another embodiment, the detection method comprising steps of providing a signalling nanostructure and detecting signal development, wherein a change in the intensity of signal. In an alternative embodiment, the target nucleic acid is a SARS-CoV-2 polynucleotide.

traducir

SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION

Publication No.: WO2022169961A1 11/08/2022

Applicant:

UNIV FLORIDA [US]

Absstract of: WO2022169961A1

The invention relates to compounds, compositions, and methods of treating viral infection, especially SARS-CoV-2 infection.

traducir

SYSTEMS AND METHODS FOR SCREENING SUBJECTS BASED ON PUPILLARY RESPONSE TO OLFACTORY STIMULATION

Publication No.: WO2022169485A1 11/08/2022

Applicant:

GREAT PLAIN TECH LLC [US]

US_2022240836_A1

Absstract of: WO2022169485A1

A system and method for screening a subject for a pupillary response to an olfactory stimulus as an indication for COVID-19. The method can include providing the olfactory stimulus to the subject via a scent dispenser, measuring a pupillary response of the subject to the olfactory stimulus via a detector, and comparing the measured pupillary response to a reference. The reference could include a default value or a characterized pupillary response for the subject or a population of individuals to the olfactory stimulus. The method can further include determining whether the subject demonstrates a diminished or an absent response to the olfactory stimulus according to whether the measured pupillary response differs from the reference by a threshold and providing an alert accordingly. The alert can include an intervention associated with COVID-19, such a recommendation to seek medical evaluation or take a COVID-19 diagnostic test.

traducir

Combinatorial Microarray Assay for Clade Variant Detection

Publication No.: US2022251635A1 11/08/2022

Applicant:

EGGERS FREDERICK HENRY [US]
KATCHMAN BENJAMIN ALAN [US]
WEN FUSHI [US]
RIVAS CANDY MAVIS [US]
NEWLAND CORY SCOTT [US]
HOGAN MICHAEL EDWARD [US]
PATHOGENDX INC [US]

Absstract of: US2022251635A1

Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant. Also provided is a method of distinguishing each clade variant from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.

traducir

Treatment of Acute Medical Conditions

Publication No.: US2022249840A1 11/08/2022

Applicant:

GALVANI BIOELECTRONICS LTD [GB]

WO_2020254793_A1

Absstract of: US2022249840A1

Electrical stimulation of neural activity in the neural innervation of the spleen that is associated with neurovascular bundles provides a useful way to treat acute medical conditions, such as trauma, hemorrhaging, shock, acute respiratory distress syndrome (ARDS), severe respiratory distress syndrome (SARS), and coronavirus disease 19 (COVID-19).

traducir

METHOD OF PREVENTING COVID-19 INFECTION

Publication No.: US2022249547A1 11/08/2022

Applicant:

HAZAN SABINE [US]

US_2021299091_A1

Absstract of: US2022249547A1

A product for preventing COVID-19 infection in an individual, the product comprising a combination of vitamin C, vitamin D, and zinc. The combination comprises 1,000 mg to 10,000 mg of vitamin C, 3,000 IU to 40,000 IU of vitamin D, and 25 mg to 75 mg of zinc. The combination is administered daily for two or more days for prophylaxis, or the combination is administered weekly over a period of two or more weeks for prophylaxis.

traducir

Compositions for managing chronic obstructive pulmonary disease

Publication No.: AU2021207536A1 11/08/2022

Applicant:

SAMI SABINSA GROUP LTD

WO_2021146648_A1

Absstract of: AU2021207536A1

The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% wVw curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung lunction during prognosis.

traducir

UNIVERSAL ANTI-CORONAVIRUS CONSERVATIVE EPITOPE IGY AND BROAD-SPECTRUM ANTI-NOVEL CORONAVIRUS IGY AND COMPOSITE ANTIBODY

Publication No.: WO2022165918A1 11/08/2022

Applicant:

SHENZHEN JASON INTELLIGENT BIOENGINEERING LTD [CN]

Absstract of: WO2022165918A1

Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention is a method for preparing the universal anti-coronavirus conservative epitope IgY and the broad-spectrum anti-variation novel coronavirus IgY antibody and an anti-mutation novel coronavirus IgY antibody and the combined antibody. Furthermore, the IgY and the composite IgY and the combined antibody can bind to a coronavirus universal conservative epitope and an antigen epitope with strong conservation, to achieve a broad-spectrum neutralizing virus effect, and the problems of coronavirus and novel coronavirus being prone to variation and immune escape and treating an asymptomatic patient are solved. Further provided in the present invention are a central air conditioner atomizing disinfectant and outer packaging disinfectant and an aerosol inhalation, spray, oral spray, nasal spray, nasal drops, eye drops, air disinfectant, hand sanitizer, powder, tablet, mouth lozenge, oral liquid and capsule made from the IgY and the composite IgY, which are used in drugs, disinfection products, health-care products and medical devices for preventing and treating coronavirus and novel coronavirus infections.

traducir

PROCESS FOR PREPARING NANOFORMULATION FOR DELIVERY OF BERBAMINE

Nº publicación: WO2022168123A1 11/08/2022

Applicant:

PANJAB UNIV CHANDIGARH [IN]

Absstract of: WO2022168123A1

The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for berbamine delivery. The process involves preparation of nanoparticles by maintaining the pH of the aqueous or lipid phase so that high drug loading of 12-50 % w/w with respect to the lipid matrix and high entrapment efficiency of more than 90% for berbamine in the solid lipid nanoparticles is achieved. The nanoformulation obtained by the process of the present invention has increased efficacy and exhibited any therapeutic property identical to free berbamine such as antiviral-cum-antibacterial agent for the treatment of microbial infections especially resistant Acinetobacter infections in treating diabetes and more specifically diabetes associated complications. Use may be extended to other diseases like COVID 19.

traducir

Page1/18 nextPage results/page

punteroimgGo back